Pharmabiz4d
Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer
Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...
Medpage Today on MSN4d
Radioligand Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer
In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...
Metastatic Castration-Sensitive Prostate Cancer Clinical Trial Pipeline Insights Featuring 35+ Companies | DelveInsight
DelveInsight's 'Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight 2024' report provides comprehensive global ...
Bayer Seeks European Approval For Third Indication For Cancer Drug Darolutamide
Bayer is seeking EMA approval for darolutamide in metastatic hormone-sensitive prostate cancer, building on promising Phase ...
Bayer Submits Application To EMA For Third Indication Of Darolutamide - Quick Facts
Bayer announced the submission of an application to the European Medicines Agency for the oral androgen receptor inhibitor ...
manilatimes6d
Orion's collaboration partner Bayer submits application for third indication of darolutamide in the EU
Orion's collaboration partner Bayer submits application for third indication of darolutamide in the EU ...